COMPANY PROFILE

Alkermes

Explore full profile

Alkermes Pharmaceutical Manufacturing and Global Biopharmaceutical Company

Dublin, IrelandFounded 1987Biotech & Life Sciences

Valuation $7.73B Market cap · 2026

Revenue $1.82B Latest reported FY

EBITDA $393M Latest reported FY

About Alkermes

Alkermes is a biopharmaceutical company focused on developing innovative medicines for people living with complex psychiatric and neurological disorders. The company leverages its deep expertise in neuroscience to create treatments that address conditions such as schizophrenia, bipolar disorder, and major depressive disorder. Alkermes operates in the healthcare and pharmaceutical market, serving patients, healthcare providers, and research institutions.

The business model of Alkermes revolves around research and development (R&D), partnerships, and commercialization. The company collaborates with leading pharmaceutical companies and research institutions to develop, manufacture, and bring to market new medicines. These partnerships are crucial for sharing resources, expertise, and accelerating the development process. Alkermes generates revenue primarily through the sale of its proprietary medicines and through licensing agreements with its partners.

Alkermes is committed to making a real impact on the lives of patients and their families. The company emphasizes a culture of safety, diversity, inclusion, and belonging, which is reflected in its numerous awards and recognitions. For instance, Alkermes received the Health Safety Excellence Award in the Life Sciences category in 2023 and the Platinum Bell Seal for Workplace Mental Health from Mental Health America.

In summary, Alkermes is a mission-driven company dedicated to advancing science and providing new treatment options for challenging psychiatric and neurological conditions. Its collaborative approach and commitment to corporate responsibility make it a notable player in the biopharmaceutical industry.

MoreLess Source: Dealroom company data

At a glance

Status: Listed
Founded: 1987
Headquarters: Dublin, Ireland
Listing: IPO 1991
Employees: 2,444
Open positions: 74
Dealroom signal: 72.5/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Trading, Biotechnology, Biotech and Pharma
Business model: Manufacturing
Client focus: b2b
Investment activity: 17 companies, latest Oct 2025
Capital deployed: $93M
Preferred round: GRANT
Links: Website LinkedIn X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

5 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
POST IPO DEBT✓Debt	Feb 2026	$0	—	BofA Securities · JPMorgan Chase & Co	↗
POST IPO EQUITY✓Other financing	Aug 2025	$0	—	BlackRock	↗

Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Revenue	Growth	EBITDA	Margin	Profit	Margin	R&D
2026	$1.8B	+23.6%	$393M	21.6%	−$90M	-4.9%	$324M
2025	$1.5B	-5.2%	$331M	22.4%	$242M	16.4%	$324M
2024	$1.6B	-6.4%	$495M	31.8%	$367M	23.6%	$245M
2023	$1.7B	+49.6%	$519M	31.2%			$271M
2022	$1.1B	-5.3%	−$96M	-8.6%
2021	$1.2B	+13%	$11M	1%
2020	$1B	—	−$52M	-5%

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Alkermes website traffic

Latest recorded traffic for Alkermes is 95K monthly website visits, up 1.1% over the last three months. Alkermes's team grew 3.5% over the past year.

Latest monthly visits95K 3-month web change+1.1% 1-year team growth+3.5%

Monthly website visitsApr 2016–Sep 2022

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

8 distinct openings shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
PBPattern BiosciencesBuilds biomolecular computers that run molecular programs in cells to treat cancer and other diseases	South San Francisco, United States	Operational	19	$55K	—
BEBeenextWe provide comprehensive R&D services in early drug discovery, from the in silico design throughout the in vitro pharmacological profiling as well as preliminary ADME properties	Turin, Italy	Operational
NBNew BiologixEngineered cell line technology that produces safe and effective AAV drugs for gene therapy, making treatments more affordable and accessible	Epalinges, Switzerland	Operational
LOLogomixLarge-scale genome engineering platform for cell therapy	Tokyo, Japan	Operational
PAPartexFirst digital pharma platform that is set to be the largest AI-powered Drug Assets Manager	Eschborn, Germany	Operational
APapricotx.comSpatially resolved cellular information company dedicated to the field of functional precision medicine, in which treatment is informed by high-plex image-based profiling of the complex drug responses of individual cells that make up each patient's unique cancer	Lucerne, Switzerland	Operational
CRCradleAI-powered protein design and engineering platform.	Amsterdam, Netherlands	Operational
KTKelonia TherapeuticsDeveloping a new wave of genetic medicines using its next generation vivo gene delivery platform	Boston, United States	Acquired